Science

Rahul Banerjee: Teclistamab and Talquetamab are approved in Mexico for triple-class exposed

Rahul Banerjee/X

Mar 4, 2025, 05:22

Rahul Banerjee: Teclistamab and Talquetamab are approved in Mexico for triple-class exposed

Rahul Banerjee, Assistant professor at Fred Hutchinson Cancer Center at the University of Washington, shared an article by Luciano J Costa, et al. on X:

“Yesterday I learned that teclistamab & talquetamab are approved in Mexico for triple-class exposed Multiple Myeloma regardless of lines of therapy Love this!

So much more practical and scientifically sound. Some day we’ll be able to ditch LOT, and it’ll be our LMIC colleagues leading the charge!”

Drug class refractoriness, not number of prior lines of therapy, properly classify patients with relapsed and refractory multiple myeloma.

Authors: Luciano J Costa, et al.

Rahul Banerjee: Teclistamab and Talquetamab are approved in Mexico for triple-class exposed

cancer fight against cancer Fred Hutchinson Cancer Center Global fight against cancer LMIC Luciano J Costa Mexico multiple myeloma OncoDaily Oncology Rahul Banerjee Talquetamab teclistamab University of Washington

Beyond the Red Carpet: Oscar Winners and Nominees Who Fought Cancer

Oncologist Near Me – Lidia Schapira: A Leader in Cancer Care and Medical Education

CancerWorld welcomes their Co-Editors-in-Chief

Dr. Manette Le Grange joins OncoDaily Editorial Board

FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Standard of Care as Perioperative Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma